Novartis AG NVS
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.41% | 2.52% | -0.91% | 1.39% | 8.47% |
| Total Other Revenue | 12.92% | -30.56% | 6.20% | 29.38% | 28.65% |
| Total Revenue | 4.67% | 0.78% | -0.70% | 2.23% | 9.00% |
| Cost of Revenue | 0.96% | 10.72% | 6.54% | 6.94% | 9.43% |
| Gross Profit | 5.89% | -2.09% | -2.95% | 0.70% | 8.86% |
| SG&A Expenses | -6.95% | -6.13% | 2.58% | -1.80% | 5.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 82.48% | -61.98% | -84.15% | 121.35% | -82.39% |
| Total Operating Expenses | -0.49% | -0.51% | 5.45% | 21.24% | 4.09% |
| Operating Income | 16.25% | 3.29% | -12.37% | -27.35% | 21.90% |
| Income Before Tax | -68.61% | -5.78% | -12.89% | -2.04% | 23.96% |
| Income Tax Expenses | -54.51% | 99.61% | -14.41% | 75.05% | 33.00% |
| Earnings from Continuing Operations | -69.57% | -19.06% | -12.55% | -14.75% | 23.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 400.00% | -58.82% | -- | 350.00% | -150.00% |
| Net Income | -69.40% | -19.23% | -12.48% | -14.51% | 23.17% |
| EBIT | 16.25% | 3.29% | -12.37% | -27.35% | 21.90% |
| EBITDA | 13.56% | 3.21% | -9.52% | -22.64% | 18.87% |
| EPS Basic | -68.91% | -17.40% | -9.77% | -11.20% | 28.68% |
| Normalized Basic EPS | 15.20% | 3.06% | -12.30% | -31.26% | 26.70% |
| EPS Diluted | -68.81% | -16.99% | -9.34% | -11.57% | 28.66% |
| Normalized Diluted EPS | 15.50% | 3.21% | -12.13% | -31.25% | 26.72% |
| Average Basic Shares Outstanding | -1.56% | -2.21% | -3.00% | -3.72% | -4.27% |
| Average Diluted Shares Outstanding | -1.80% | -2.35% | -3.18% | -3.74% | -4.29% |
| Dividend Per Share | -- | -- | -- | 20.81% | -- |
| Payout Ratio | -- | 0.43% | 0.33% | -- | -- |